inmune
bio
host
key
opinion
leader
webinar
treatment
resistant
depression
tuesday
september
la
jolla
globe
newswire
inmune
bio
nasdaq
inmb
company
immunology
company
focused
developing
treatments
harness
patient
innate
immune
system
fight
disease
today
announced
company
hosting
key
opinion
leader
kol
webinar
topic
treatment
resistant
depression
trd
et
tuesday
september
webinar
discuss
role
neuroinflammation
trd
feature
presentations
two
thought
leaders
field
charles
raison
professor
department
psychiatry
university
wisconsin
madison
john
schneider
chief
executive
officer
principal
avalon
health
economics
inmune
bio
recently
awarded
million
small
business
innovation
research
sbir
grant
disbursed
company
stages
national
institutes
health
nih
support
phase
study
lead
clinical
candidate
patients
trd
management
provide
overview
trial
design
register
access
live
webinar
click
use
link
https
webinar
register
date
september
time
pm
eastern
time
charles
raison
professor
department
psychiatry
university
wisconsin
madison
raison
mary
sue
mike
shannon
chair
healthy
minds
children
families
school
human
ecology
professor
department
psychiatry
university
wisconsin
madison
raison
received
medical
degree
washington
university
st
louis
missouri
elected
alpha
omega
alpha
missouri
state
medical
association
award
completed
residency
training
ucla
neuropsychiatric
institute
hospital
los
angeles
addition
medical
training
raison
obtained
masters
english
university
denver
raison
written
published
scientific
papers
well
review
papers
editorials
chapters
written
featured
books
written
two
books
recently
new
science
depression
published
ww
norton
raison
publications
cited
times
three
publications
citations
recipient
several
teaching
awards
raison
received
research
funding
national
institute
mental
health
national
center
complementary
alternative
medicine
centers
disease
control
prevention
visionary
work
focuses
treatment
depression
response
illness
stress
translating
neurobiological
findings
novel
interventions
addition
activities
university
raison
mental
health
expert
john
schneider
chief
executive
officer
founder
avalon
health
economics
john
schneider
ceo
founder
avalon
health
economics
schneider
one
founding
partners
health
economics
consulting
group
llc
hecg
formed
hecg
merged
oxford
outcomes
schneider
served
senior
director
health
economics
operations
oxford
outcomes
also
included
facilitating
integration
oxford
outcomes
icon
plc
started
avalon
health
economics
bringing
together
consulting
practices
several
industry
academic
colleagues
building
started
hecg
prior
starting
hecg
schneider
faculty
department
health
management
policy
department
economics
university
iowa
health
services
policy
analysis
university
california
berkeley
concentration
health
economics
years
experience
studying
economic
organizational
aspects
health
care
industry
including
professional
appointments
center
health
economics
research
waltham
part
rti
international
california
association
health
plans
sacramento
ca
schneider
also
served
consultant
managed
care
organizations
state
health
departments
trade
associations
medical
device
manufacturers
large
pharmaceutical
companies
others
research
published
medical
care
research
review
international
journal
healthcare
finance
economics
tobacco
control
health
economics
review
health
affairs
inquiry
health
services
research
review
industrial
organization
international
journal
technology
assessment
health
care
american
journal
medical
science
prevention
science
health
care
financing
review
business
health
aei
press
disclaimer
research
reported
publication
supported
national
institute
mental
health
national
institutes
health
award
number
content
solely
responsibility
authors
necessarily
represent
official
views
national
institutes
health
inhibitor
tumor
necrosis
factor
tnf
acts
differently
currently
existing
tnf
inhibitors
neutralizes
soluble
tnf
stnf
without
affecting
tnf
tmtnf
tnf
receptors
could
substantial
beneficial
effects
patients
neurologic
disease
decreasing
neuroinflammation
information
importance
targeting
neuroinflammation
brain
improve
cognitive
function
restore
neuronal
communication
visit
section
inmune
bio
website
inmune
bio
inmune
bio
inc
publicly
traded
nasdaq
inmb
biotechnology
company
focused
developing
treatments
target
innate
immune
system
fight
disease
inmune
bio
two
product
platforms
product
platform
utilizes
technology
selectively
neutralize
soluble
tnf
key
driver
innate
immune
dysfunction
mechanistic
target
many
diseases
currently
developed
complications
cancer
alzheimer
treatment
resistant
depression
nash
natural
killer
cell
priming
platform
includes
aimed
priming
patient
nk
cells
eliminate
minimal
residual
disease
patients
cancer
inmune
bio
product
platforms
utilize
precision
medicine
approach
treatment
wide
variety
hematologic
malignancies
solid
tumors
chronic
inflammation
learn
please
visit
forward
looking
statements
clinical
trials
early
stages
assurance
specific
outcome
achieved
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
contained
herein
based
current
expectations
subject
number
risks
uncertainties
actual
results
timing
certain
events
circumstances
may
differ
materially
described
statements
result
risks
uncertainties
livnate
inkmune
still
clinical
trials
preparing
start
clinical
trials
approved
assurance
approved
specific
results
achieved
two
platforms
beginning
clinical
trials
assurance
success
trials
factors
could
cause
actual
future
results
differ
materially
current
expectations
include
limited
risks
uncertainties
relating
company
ability
produce
drug
clinical
trials
availability
substantial
additional
funding
company
continue
operations
conduct
research
development
clinical
studies
future
product
commercialization
company
business
research
product
development
regulatory
approval
marketing
distribution
plans
strategies
factors
identified
described
detail
company
filings
securities
exchange
commission
including
company
annual
report
form
company
quarterly
reports
form
company
current
reports
form
company
assumes
obligation
update
statements
order
reflect
event
circumstance
may
arise
date
release
inmune
bio
contact
david
moss
cfo
dmoss
investor
contact
chuck
padala
lifesci
advisors
chuck
